NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $17.46 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$17.43 -0.03 (-0.17%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lyell Immunopharma Stock (NASDAQ:LYEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyell Immunopharma alerts:Sign Up Key Stats Today's Range$16.85▼$17.6950-Day Range$16.13▼$24.8952-Week Range$7.65▼$45.00Volume54,336 shsAverage Volume64,954 shsMarket Capitalization$407.34 millionP/E RatioN/ADividend YieldN/APrice Target$43.00Consensus RatingModerate Buy Company Overview Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment. The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers. Early-stage candidates utilize technologies aimed at epigenetic reprogramming of T cells to improve their ability to expand, traffic to tumor sites and maintain durable anti-tumor activity. Lyell partners with academic centers and contract research organizations to advance its lead programs through IND-enabling studies and into clinical trials. Founded in 2017 and headquartered in South San Francisco, Lyell Immunopharma was established by a team of immunologists and cell therapy experts. The company has raised venture funding from leading life science investors and maintains research and manufacturing operations in the San Francisco Bay Area. Under the leadership of co-founder and CEO David Chang, Lyell is building a translational research engine designed to accelerate the discovery, development and manufacturing of engineered T cell products for patients with high-unmet-need cancers.AI Generated. May Contain Errors. Read More Lyell Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreLYEL MarketRank™: Lyell Immunopharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 579th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLyell Immunopharma has a consensus price target of $43.00, representing about 146.3% upside from its current price of $17.46.Amount of Analyst CoverageLyell Immunopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lyell Immunopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($8.37) to ($9.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lyell Immunopharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.14% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 18.78, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently increased by 8.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.50 News SentimentLyell Immunopharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lyell Immunopharma this week, compared to 2 articles on an average week.Search Interest6 people have searched for LYEL on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders6.20% of the stock of Lyell Immunopharma is held by insiders.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYEL Stock News HeadlinesLyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum TranscriptMay 23 at 1:01 AM | seekingalpha.comLyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference TranscriptMay 22, 2026 | seekingalpha.comNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 26 at 1:00 AM | Porter & Company (Ad)Lyell Immunopharma COO Hill sells $1.5k in sharesMay 19, 2026 | investing.comQ1 Earnings Estimate for LYEL Issued By HC WainwrightMay 18, 2026 | americanbankingnews.comLyell Immunopharma Announces Participation in May Investor ConferencesMay 12, 2026 | globenewswire.comBank of America Securities Reaffirms Their Sell Rating on Lyell Immunopharma (LYEL)May 6, 2026 | theglobeandmail.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026May 6, 2026 | globenewswire.comSee More Headlines LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $30.78 at the beginning of 2026. Since then, LYEL shares have decreased by 43.3% and is now trading at $17.46. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its quarterly earnings data on Wednesday, May, 6th. The company reported ($1.10) EPS for the quarter, hitting the consensus estimate of ($1.10). The firm earned $0 million during the quarter, compared to the consensus estimate of $0 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative trailing twelve-month return on equity of 85.71%. When did Lyell Immunopharma's stock split? Lyell Immunopharma's stock reverse split on the morning of Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Tuesday, June 15th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO. Who are Lyell Immunopharma's major shareholders? Top institutional investors of Lyell Immunopharma include Renaissance Technologies LLC (0.50%), Dimensional Fund Advisors LP (0.21%), RBF Capital LLC (0.19%) and Bank of America Corp DE (0.14%). Insiders that own company stock include Lynn Seely, Lynn Seely, Richard Klausner, Richard Klausner, Stephen J Hill, Gary K Lee, Veronica Sanchez Bulis, Sumant Ramachandra, Charles W Newton, Charles W Newton, Otis W Brawley and Otis W Brawley. View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyell Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/06/2026Today5/26/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, LYEL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LYEL CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees270Year Founded2018Price Target and Rating Average Price Target for Lyell Immunopharma$43.00 High Price Target$49.00 Low Price Target$34.00 Potential Upside/Downside+146.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($13.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$274.45 million Net Margins-794,858.12% Pretax Margin-794,858.06% Return on Equity-85.71% Return on Assets-66.41% Debt Debt-to-Equity RatioN/A Current Ratio7.23 Quick Ratio7.23 Sales & Book Value Annual Sales$40 thousand Price / Sales10,183.55 Cash FlowN/A Price / Cash FlowN/A Book Value$11.73 per share Price / Book1.49Miscellaneous Outstanding Shares23,330,000Free Float21,887,000Market Cap$407.34 million OptionableOptionable Beta-0.05 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:LYEL) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LYEL Stock Alerts